SKYE NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Skye Bioscience, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.57 USD
-12.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -26.2% below the Trend Line and sits at 0.2% of its 52-week range. The latest completed week returned -12.8%, after a -18.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 48/100. Near-term considerations: earnings are due in 4d.

Setup score 21 out of 100
Latest Close 0.57 USD 31 Jul 2026
1W Return -12.8% latest completed week
4W Return -18.8% short-term follow-through
12W Return -34.1% quarterly tape
Trend Breadth 19.2% 10 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -12.8% Latest completed week; four-week move -18.8%. Indicator stack 11/39 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 343.0%. News sentiment 48/100 43 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -26.2% below the Trend Line and sits at 0.2% of its 52-week range. The latest completed week returned -12.8%, after a -18.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0412-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.04Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -18.8% over four weeks, -34.1% over 12 weeks, and -83.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-12.8%
4W-18.8%
12W-34.1%
26W-43.7%
52W-83.3%
Active trend streak0 weeks
Active weeks in one year10
Trend breadth19.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.10Latest activity-pressure read.
Pressure change-111.9%Four-week change in activity pressure.
Leadership-64.87Latest relative-leadership reading.
RS change0.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength38/100Blend of value, momentum, and quality. Underlying universe rank 63; rank 1 is best.
Value44/100Relative valuation strength. Underlying universe rank 57; rank 1 is best.
Quality43/100Profitability and accounting quality. Underlying universe rank 58; rank 1 is best.
Momentum44/100Medium-term price momentum. Underlying universe rank 57; rank 1 is best.
Growth44/100Revenue and earnings growth. Underlying universe rank 57; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-281.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-3661.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

SKYE shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.11, expected move of 343.0%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move343.0%
Put/call volume0.11
Pressure91
Speculation18
Volatility96
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 43 relevant articles.

7 positive · 27 neutral · 9 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move343.0%Nearest-chain priced movement where available.
52-week drawdown-88.6%Distance below the 52-week high.
13-week volatility5.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+23.0%Week of 24 Apr.
Worst week-18.9%Week of 6 Feb.
Latest week-12.8%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains4
Flat weeks0
Modest losses4
Sharp losses12
Recent vol5.7%13-week weekly-return volatility.
Base vol13.0%52-week weekly-return volatility.
Up/down split23/28Count of positive and negative weeks in the 52-week window.
Average skew7.8% / -10.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape23/100

Trend, activity pressure, participation, and risk combine to a 23/100 tape read.

 Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.04; No reversal markers Factors41/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 52 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options35/100

SKYE shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.11, expected move of 343.0%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 343.0% Sentiment48/100

Weighted news tone is neutral across 43 relevant articles.

Skye Bioscience, Inc. Revenue Breakdown – NASDAQ:SKYE Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.57 USD-12.8%0.77 USD3.81 USD-0.10-64.87790.7KOff
24 Jul 20260.65 USD0.4%0.78 USD3.84 USD0.25-61.19325.9KOff
17 Jul 20260.65 USD-5.9%0.79 USD3.88 USD0.50-63.67933.2KOff
10 Jul 20260.69 USD-1.5%0.80 USD3.91 USD0.68-64.59391.7KOff
3 Jul 20260.70 USD3.0%0.81 USD3.94 USD0.88-64.97484.3KOff
26 Jun 20260.68 USD-3.9%0.83 USD3.97 USD0.94-67.35582.0KOff
19 Jun 20260.71 USD-10.1%0.85 USD4.00 USD1.04-68.89631.3KOff
12 Jun 20260.79 USD7.4%0.86 USD4.03 USD1.11-65.14934.7KOff
5 Jun 20260.73 USD-5.4%0.88 USD4.06 USD1.13-67.351.1MOff
29 May 20260.78 USD-6.5%0.91 USD4.08 USD1.16-67.72805.2KOff
22 May 20260.83 USD1.9%0.93 USD4.09 USD1.16-65.05739.9KOff
15 May 20260.81 USD-5.7%0.95 USD4.11 USD1.18-65.81946.8KOff
8 May 20260.86 USD4.8%0.97 USD4.13 USD1.05-64.37689.3KOff
1 May 20260.82 USD-15.1%1.00 USD4.15 USD0.81-64.621.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.